Antitubercular nanocarrier combination therapy: Formulation strategies and in vitro efficacy for rifampicin and SQ641

Molecular Pharmaceutics

Volumn 12, Issue 5, 2015, Pages 1554-1563

  Daddio, Suzanne M ^a,d   Reddy, Venkata M ^b   Liu, Ying ^a,e   Sinko, Patrick J ^c   Einck, Leo ^b   Prudhomme, Robert K ^a  

^a Princeton University   (United States)

^b SEQUELLA INC   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e University of Illinois at Chicago   (United States)

Author keywords

block copolymer; flash nanoprecipitation; isoniazid; nanocarrier; nanoparticle; prodrug; rifampicin; SQ641; tuberculosis

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; CYCLOSPORIN A; ESTER; ISONIAZID; NANOCARRIER; PRODRUG; RIFAMPICIN; SQ 641; UNCLASSIFIED DRUG; CYCLOSPORIN; NANOPARTICLE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIVISION; CHEMICAL BOND; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; HYDROLYSIS; HYDROPHOBICITY; IN VITRO STUDY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; CHEMISTRY; DRUG EFFECTS; MICROBIOLOGY;

ANTITUBERCULAR AGENTS; CYCLOSPORINE; ISONIAZID; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; RIFAMPIN; VITAMIN E;

EID: 84929191572     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5008663     Document Type: Article

References (42)

1. Global Tuberculosis Report; World Health Organization: Geneva, Switzerland, 2013.
2. Schutz, I. A comparison of rifampicin, ethambutol and PAS in short-term monotherapy. Preliminary results of the third cooperative study of the WATL Acta Tuberc. Pneumol. Belg. 1969, 60, 437-41
3. Jindani, A.; Aber, V. R.; Edwards, E. A.; Mitchison, D. A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis Am. Rev. Respir. Dis. 1980, 121, 939-949
4. Yoder, M. A.; Lamichhane, G.; Bishai, W. R. Cavitary pulmonary tuberculosis: the Holy Grail of disease transmission Curr. Sci. 2004, 86, 74-81
5. El-Sadr, W. M.; Perlman, D. C.; Denning, E.; Matts, J. P.; Cohn, D. L. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes Clin. Infect. Dis. 2001, 32, 623-632
6. Pandey, R.; Zahoor, A.; Sharma, S.; Khuller, G. K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis Tuberculosis 2003, 83, 373-378
7. Gelperina, S.; Kisich, K.; Iseman, M. D.; Heifets, L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis Am. J. Resp. Crit. Care Med. 2005, 172, 1487-1490
8. Azarmi, S.; Roa, W. H.; Loebenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases Adv. Drug Delivery Rev. 2008, 60, 863-875
9. Yee, D.; Valiquette, C.; Pelletier, M.; Parisien, I.; Rocher, I.; Menzies, D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am. J. Resp. Crit. Care Med. 2003, 167, 1472-1477
10. Blasi, P.; Schoubben, A.; Giovagnoli, S.; Rossi, C.; Ricci, M. Fighting tuberculosis: old drugs, new formulations Expert Opin. Drug Delivery 2009, 6, 977-993
11. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis Nature 2011, 469, 483-490
12. Palomino, J. C.; Ramos, D. F.; da Silva, P. A. New anti-tuberculosis drugs: strategies, sources and new molecules Curr. Med. Chem. 2009, 16, 1898-1904
13. Kaufmann, S. H. E. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 2001, 1, 20-30
14. Anisimova, Y. V.; Gelperina, S. I.; Peloquin, C. A.; Heifets, L. B. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages J. Nanopart. Res. 2000, 2, 165-171
15. Muttil, P.; Wang, C. C.; Hickey, A. J. Inhaled drug delivery for tuberculosis therapy Pharm. Res. 2009, 26, 2401-2416
16. Pandey, R.; Ahmad, Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future Nanomedicine 2011, 7, 259-272
17. DAddio, S. M.; Baldassano, S.; Shi, L.; Cheung, L.; Adamson, D. H.; Bruzek, M.; Anthony, J. E.; Laskin, D. L.; Sinko, P. J.; Prudhomme, R. K. Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers J. Controlled Release 2012, 168, 41-49
18. Tuberculosis. Current Topics in Microbiology and Immunology; Shinnick, T. M., Ed.; Springer-Verlag: New York, 1996.
19. Reddy, V. M.; Bogatcheva, E.; Protopopova, M. Enhancement of Intracellular Activity of Capuramycin (CM) Analogue SQ641 against M. tuberculosis (MTB), abstract C1-3851, 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 24-28, 2008.
20. Reddy, V. M.; Einck, L.; Nacy, C. A. In vitro antimycobacterial activities of capuramycin analogues Antimicrob. Agents Chemother. 2008, 52, 719-721
21. Nikonenko, B. V.; Reddy, V. M.; Protopopova, M.; Bogatcheva, E.; Einck, L.; Nacy, C. A. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis Antimicrob. Agents Chemother. 2009, 53, 3138-3139
22. Qian, H. T.; Wohl, A. R.; Crow, J. T.; Macosko, C. W.; Hoye, T. R. A strategy for control of "random"copolymerization of lactide and glycolide: application to synthesis of PEG- b -PLGA block polymers having narrow dispersity Macromolecules 2011, 44, 7132-7140
23. Zhang, S. Y.; Adamson, D. H.; Prudhomme, R. K.; Link, A. J. Photocrosslinking the polystyrene core of block-copolymer nanoparticles Polym. Chem. 2011, 2, 665-671
24. Han, J.; Zhu, Z.; Qian, H.; Wohl, A. R.; Beaman, C. J.; Hoye, T. R.; Macosko, C. W. A simple confined impingement jets mixer for flash nanoprecipitation J. Pharm. Sci. 2012, 10, 4018-4023
25. Johnson, B. K.; Prudhomme, R. K. Engineering the Direct Precipitation of Stabilized Organic and Block Copolymer Nanoparticles as Unique Composites, The 226th ACS National Meeting, New York, NY, September 7-11, 2003.
26. Liu, Y.; Cheng, C. Y.; Liu, Y.; Prudhomme, R. K.; Fox, R. O. Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation Chem. Eng. Sci. 2008, 63, 2829-2842
27. Snewin, V. A.; Gares, M. P.; Gaora, P. O.; Hasan, Z.; Brown, I. N.; Young, D. B. Assessment of immunity to mycobacterial infection with luciferase reporter constructs Infect. Immun. 1999, 67, 4586-4593
28. Luna-Herrera, J.; Reddy, M. V.; Gangadharam, P. R. J. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli Antimicrob. Agents Chemother. 1995, 39, 440-444
29. DAddio, S. M.; Saad, W.; Ansell, S. M.; Squiers, J. J.; Adamson, D. H.; Herrera-Alonso, M.; Wohl, A. R.; Hoye, T. R.; Macosko, C. W.; Mayer, L. D.; Vauthier, C.; Prudhomme, R. K. Effects of block copolymer properties on nanocarrier protection from in vivo clearance J. Controlled Release 2012, 162, 208-217
30. Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S. W.; Shu, Y.; Harasym, T. O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prudhomme, R. K.; Mayer, L. D. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates J. Med. Chem. 2008, 51, 3288-3296
31. Navidi, W. C. Statistics for Engineers and Scientists, 1 st ed.; McGraw Hill Higher Education: New York, 2006.
32. Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prudhomme, R. K.; Mayer, L. D. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates J. Med. Chem. 2008, 51, 3288-96
33. DAddio, S. M.; Prudhomme, R. K. Controlling drug nanoparticle formation by rapid precipitation Adv. Drug Delivery Rev. 2011, 63, 417-426
34. Mahajan, A. J.; Kirwan, D. J. Nucleation and growth kinetics of biochemicals measured at high supersaturations J. Cryst. Growth 1994, 144, 281-290
35. Akbulut, M.; Ginart, P.; Gindy, M. E.; Theriault, C.; Chin, K. H.; Soboyejo, W.; Prudhomme, R. K. Generic method of preparing multifunctional fluorescent nanoparticles using flash nanoprecipitation Adv. Funct. Mater. 2009, 19, 718-725
36. Gratton, S. E. A.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, J. M. The effect of particle design on cellular internalization pathways Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11613-11618
37. Kumar, V.; Hong, S. Y.; Maciag, A. E.; Saavedra, J. E.; Adamson, D. H.; Prudhomme, R. K.; Keefer, L. K.; Chakrapani, H. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles Mol. Pharmaceutics 2010, 7, 291-298
38. Belandria, V.; Mohammadi, A. H.; Richon, D. Volumetric properties of the (tetrahydrofuran plus water) and (tetra-n-butyl ammonium bromide plus water) systems: Experimental measurements and correlations J. Chem. Thermodyn. 2009, 41, 1382-1386
39. Liow, J. S.; Lu, S. Y.; McCarron, J. A.; Hong, J. S.; Musachio, J. L.; Pike, V. W.; Innis, R. B.; Zoghbi, S. S. Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [C-11](R)-(-)-RWAY Synapse 2007, 61, 96-105
40. Amaral, L.; Martins, M.; Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps Antimicrob. Agents Chemother. 2007, 59, 1237-1246
41. Rockett, K. A.; Brookes, R.; Udalova, I.; Vidal, V.; Hill, A. V. S.; Kwiatkowski, D. 1,25-Dihydroxyvitamin D-3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line Infect. Immun. 1998, 66, 5314-5321
42. Wohl, A. R.; Han, J.; Guru, B. R.; Panyam, J.; Hoye, T. R.; Macosko, C. W. In Silicate Prodrug-Loaded Nanoparticles, AIChE Annual Meeting, Minneapolis, MN, October 16-21, 2011.